Bacterial infection treatment developer Spero Therapeutics has filed to raise up to $86.3m in an initial public offering that will enable a host of corporates to exit.

Allena Pharmaceuticals, a Pharmstandard-backed developer of metabolic and kidney disorder treatments, has filed to go public after raising $93m in venture capital.

ImaginAb, which has now raised approximately $4m in total, will continue development of the imaging agent it is developing for T-cell tumours.

The protective clothing developer has now raised more than $36m in total, after closing a round that included Northwell Ventures and Mercy Health.

The ophthalmology-focused drug developer, which is backed by pharmaceutical company Novo, plans to use the money to further test its lead product candidate.

Beta Bionics has been launched as a public benefit corporation to commercialise automated bihormonal pumps for type 1 diabetes sufferers.

The seven programs, formed between two University of Maryland institutions, UMB and UMCP, include a commercialisation vehicle for high-potential spinouts.

The digital health platform has raised $6.5m in a round backed by Al Rashed and Sons unit Rimco Investments, and will use the funding for regional expansion.